Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 3/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.49 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539742 | 1.00 | CDK9 (0.49) | CDK9CCNT1SHMT2LIMK1ALOX15 | |
| SCHEMBL2520219 | 0.86 | CDK9 (0.58) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL2520216 | 0.86 | CDK9 (0.58) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL30462020 | 0.82 | ALDH1A1 (0.49) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL2526250 | 0.82 | ALDH1A1 (0.49) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL2526248 | 0.82 | ALDH1A1 (0.49) | CDK9CCNT1ALOX15TSHRMAPK1 | |
| SCHEMBL2542379 | 0.81 | CDK9 (0.48) | CDK9CCNT1LIMK1ALOX15TSHR | |
| SCHEMBL2542384 | 0.81 | CDK9 (0.48) | CDK9CCNT1LIMK1ALOX15TSHR | |
| SCHEMBL38657760 | 0.79 | ALOX15 (0.43) | CDK9CCNT1SHMT2LIMK1ALOX15 | |
| SCHEMBL7717920 | 0.79 | SMN1; SMN2 (0.44) | CDK9CCNT1SHMT2ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560975-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | disclosed |
| EP-2560975-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8492376-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492376-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2560975-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131596-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131596-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1A, AVPR1B, OXTR | CDK9 3225/4885CCNT1 1676/4885SHMT2 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.